3C-E
4-ethoxy-3,5-dimethoxyamphetamine
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
3C-E (3,5-dimethoxy-4-ethoxyamphetamine) is a synthetic psychedelic of the phenethylamine class. It is the α-methylated structural analog of escaline and a mid-potency member of the 3C mescaline-derivative series. 3C-E is a 5-HT₂A receptor agonist,[1] producing its effects by directly activating serotonin receptors without releasing stored monoamines.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, DOx series, 2C-x series show less
Synthesized by Alexander Shulgin and documented as entry #25 in PiHKAL (1991),[3] 3C-E emerged from systematic exploration of the mescaline pharmacophore. No pharmaceutical company or research institution has developed the compound, and no clinical trials have been conducted. It remains an uncommon research chemical, unscheduled by name in most jurisdictions but potentially prosecutable under analog legislation.
Subjective effects include geometric visual patterns, color enhancement, closed-eye imagery, and body load. The experience is defined by the tension between rich, jewel-like visual phenomena and a persistent somatic heaviness — nausea, trembling, and muscle tension that foregrounds the body throughout the session.[4] Bruxism, pre-nausea discomfort, and generalized physical unease are characteristic unsought effects.
3C-E produces no physical dependence; rapid tolerance develops via 5-HT₂A receptor mechanisms, making compulsive redosing self-limiting.[5] The primary acute risk is a steep dose-response curve where modest increases produce disproportionate intensification of both somatic and psychological effects.[4] No controlled studies exist — the current understanding rests on Shulgin's bioassays, one mouse behavioral pharmacology study,[1] and structural analogy to the mescaline class.
History[edit]
Discovery
3C-E was first synthesized by Alexander Shulgin at his private laboratory in Lafayette, California, and published as entry #25 in PiHKAL: A Chemical Love Story (1991).[3] The compound arose from two intersecting structural modifications to mescaline: replacement of the 4-methoxy group with an ethoxy group, and extension of the aminoethyl chain to an amphetamine chain. Shulgin and a small group of research subjects evaluated it orally at 30–60 mg, reporting vivid closed-eye visuals alongside notably heavy body load.[4]
Research significance
No pharmaceutical company or clinical institution has developed 3C-E, and no clinical trials have been registered. Its primary scientific contribution came in 2019, when Halberstadt et al. included it in a systematic comparison of mescaline structural analog pharmacology using the mouse head-twitch response assay, confirming dose-dependent serotonin 2A receptor agonist activity and demonstrating that 4-ethoxy substitution increases potency relative to the parent compound TMA.[1]
Prohibition and modern status
3C-E is not specifically named in most drug schedules. In the United States it is potentially prosecutable under the Federal Analogue Act as an analog of Mescaline.[6] The United Kingdom prohibited it under the Psychoactive Substances Act 2016, and Germany controlled it under the NpSG effective November 2016.[6] It circulates in small quantities among research chemical users.
The "3C" designation refers to the three-carbon aminopropyl side chain that distinguishes this amphetamine series from the two-carbon phenethylamine parent compounds (the 2C series). 3C-E itself denotes the ethoxy substitution at the 4-position — "E" for ethoxy.
Chemistry[edit]
Structural class
3C-E belongs to the 3C series of amphetamine psychedelics — the α-methylated homologs of mescaline-derived phenethylamines. All 3C compounds share the 3,4,5-trisubstituted phenyl ring of Mescaline coupled to a three-carbon aminopropyl side chain rather than the two-carbon chain of the parent phenethylamines.[4]
The defining feature of 3C-E relative to TMA (3,4,5-trimethoxyamphetamine) is replacement of the 4-position methoxy group with an ethoxy group. This single-carbon extension increases lipophilicity at the 4-position and enhances potency.[1] 3C-E is thus the amphetamine structural analog of escaline and the 4-ethoxy analog of TMA.
Molecular identity
| Molecular formula | C₁₃H₂₁NO₃ |
| Molecular weight | 239.31 g/mol |
The molecule consists of a benzene ring bearing methoxy groups at positions 3 and 5, an ethoxy group at position 4, and a 2-aminopropyl chain at position 1. The 3,4,5-substitution pattern distinguishes the mescaline/TMA/3C series from the 2,5-dimethoxy series (DOx, 2C-x compounds), which follow different structure-activity rules — notably, extending the 4-position alkoxy group increases potency in the 3,4,5 series but not in the 2,5-dimethoxy series.[1]
Structure-activity relationships
The enhanced potency of α-methylated phenethylamines (amphetamine-type) over their two-carbon counterparts is well-established across the class. Parrish et al. demonstrated that phenylisopropylamine analogs produce greater 5-HT₂A receptor activation than their phenethylamine counterparts.[7] The 3,5-methoxy groups in the mescaline pharmacophore must remain conformationally mobile for receptor activation, unlike the constrained 2,5-dimethoxy series.[8]
Stereochemistry
3C-E has a chirality center at the α-carbon, yielding (R)- and (S)-enantiomers. All published experimentation used racemic mixture material.[4] No enantiopure synthesis has been published. By analogy with other phenylisopropylamine 5-HT₂A agonists, the (R)-enantiomer is expected to be more active.[7]
Physical properties
Shulgin reported the hydrochloride salt as a white crystalline solid.[4] No melting point, solubility, or stability data have been published in the peer-reviewed literature.
Pharmacology[edit]
Mechanism of action
3C-E activates serotonin 5-HT₂A receptors directly, without releasing stored monoamines. The most direct evidence comes from Halberstadt et al. (2019), who demonstrated dose-dependent induction of the head-twitch response in mice — a well-validated behavioral marker of 5-HT₂A activation — with potency exceeding that of the parent compound TMA.[1]
No in vitro binding data have been published for 3C-E itself. The mechanistic assignment rests on behavioral pharmacology and structural class membership. Microdialysis data from the parent scaffold TMA show no detectable changes in extracellular serotonin or dopamine, and no meaningful inhibition of monoamine oxidase.[2] 3C-E, differing only by one carbon at the 4-position alkoxy group, is expected to share this profile.inferred
The head-twitch response assay correlates strongly with human psychedelic potency across dozens of compounds (r = 0.9448),[9] supporting 3C-E's classification as a psychedelic active in humans at the doses Shulgin reported.
Pharmacokinetics
No human or animal pharmacokinetic data exist for 3C-E. The following parameters are inferred from Shulgin's bioassays and structural analogy to related phenylalkylamines.inferred
Oral administration produces effects within 1–2 hours according to available reports, though Shulgin's PiHKAL entry does not specify onset time.[4] Total duration is 8–12 hours at 30–60 mg oral.[4]
Metabolism is expected to involve breakdown of the aromatic alkoxy groups in the liver. Related compounds in the dimethoxyamphetamine family are metabolized primarily by CYP2D6,[10] though this finding comes from the 2,5-dimethoxy series rather than the 3,5-dimethoxy series and requires direct confirmation.inferred Bioavailability, half-life, and clearance have not been characterized.
Neuroscience[edit]
Where it acts
3C-E activates 5-HT₂A receptors concentrated on the outer branches of neurons in the prefrontal and association cortices — regions governing perception, cognition, and self-referential processing. This activation increases cortical excitability and disrupts the brain's normal filtering of sensory information through thalamic relay circuits. The absence of monoamine release by the parent scaffold TMA[2] suggests that 3C-E's neural effects are mediated through direct postsynaptic receptor signaling rather than the presynaptic monoamine flooding characteristic of empathogenic amphetamines.
Why it matters
The REBUS (relaxed beliefs under psychedelics) framework proposes that 5-HT₂A agonists loosen the brain's high-level predictions, allowing raw sensory signals greater influence over perception. 3C-E's reported combination of vivid visual phenomena with intact self-awareness at moderate doses is consistent with partial relaxation of these predictive models — enough to produce novel visual percepts without complete dissolution of the sense of self.
Serotonergic psychedelics also promote structural brain changes through neuroplasticity pathways. Whether 3C-E activates these pathways at pharmacologically relevant doses has not been investigated.
Does 3C-E produce the same patterns of brain network disruption seen with psilocybin and LSD? The mescaline pharmacophore acts through 5-HT₂A, but its distinct binding profile could produce qualitatively different network-level effects.
Subjective Effects[edit]
The 3C-E experience is distinguished from most psychedelic phenethylamines by the prominence of its somatic component. Body load — nausea, trembling, muscle tension, and generalized heaviness — is not incidental but a defining feature that shapes the session, particularly above 40 mg. The visual and cognitive effects are reported as rich and jewel-like when present, but the physical foreground demands significant tolerance for discomfort.[4] Set and setting influence the psychological dimension but do not meaningfully mitigate the body load.
Relative to mescaline, 3C-E is more potent on a milligram basis and carries heavier body load per unit of visual effect. Compared to the DOx series, it shares the extended duration but arises from a different regiochemistry (3,5-dimethoxy versus 2,5-dimethoxy) with distinct structure-activity characteristics.[1]
Effect Grid
Full psychedelic experience with clear visual phenomena — color enhancement, visual drifting, and closed-eye geometry featuring bright, jewel-like imagery. Internal hallucinations with complex fantasy elements emerge. Thought connectivity and conceptual thinking become prominent, with time alteration creating a sense of temporal distortion.
Body load is the defining somatic feature at this tier. Nausea, muscle tension, bruxism, and spontaneous body sensations are common and may dominate the first 1-2 hours. Stimulation is sustained, with pronounced wakefulness. Shulgin reported that 40 mg produced a strong sense of control, while 60 mg brought vivid visuals alongside significant body discomfort — the dose-response between these points is steep.
Sleep is impossible for 8+ hours. The full experience commitment is 10-14 hours including aftereffects. Food intake will be minimal. Adequate hydration is important given dehydration sensation and excessive sweating.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Geometry · Visual breathing · Touch enhancement · Depth perception distortion · Tracers · Perspective distortion · Auditory enhancement · Environmental patterning · Light sensitivity · Visual morphing · Symmetrical texture repetition · After-images · Peripheral vision distortion · Sound sensitivity · Visual melting · Synesthesia · Visual acuity enhancement · Visual diffraction · Auditory distortion · Holotropic state · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Auditory misinterpretation · Dreaming enhancement · Vestibular distortion · Object transformations · Flashbacks · Internal hallucinations · External hallucinations · Object activation · Visual recursion · Environmental orbism / cubism · Auditory hallucinations · Persisting hallucinations
Tracers · Perspective distortion · Auditory enhancement · Environmental patterning · Light sensitivity · Visual morphing · Symmetrical texture repetition · After-images · Peripheral vision distortion · Sound sensitivity · Visual melting · Synesthesia · Visual acuity enhancement · Visual diffraction · Auditory distortion · Holotropic state · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Auditory misinterpretation · Dreaming enhancement · Vestibular distortion · Object transformations · Flashbacks · Internal hallucinations · External hallucinations · Object activation · Visual recursion · Environmental orbism / cubism · Auditory hallucinations · Persisting hallucinations
Body high · Insomnia · Stimulation · Spontaneous body sensations · Nausea · Dry mouth · Dehydration sensation · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Excessive sweating · Muscle tension · Dizziness · Vibrations / buzzing · Increased urination · Bruxism · Involuntary body movements · Temperature dysregulation · Body schema distortion · Headache · Trembling · Vomiting · Abnormal heartbeat · Diarrhea · Salivation · Motor control enhancement · Seizure threshold reduction · Tactile hallucination
Spontaneous body sensations · Nausea · Dry mouth · Dehydration sensation · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Excessive sweating · Muscle tension · Dizziness · Vibrations / buzzing · Increased urination · Bruxism · Involuntary body movements · Body schema distortion · Headache · Trembling · Vomiting · Abnormal heartbeat · Diarrhea · Salivation · Motor control enhancement · Seizure threshold reduction · Tactile hallucination
Aesthetic enhancement · Openness enhancement · Cognitive euphoria · Immersion enhancement · Pattern recognition enhancement · Cognitive flexibility · Introspection enhancement · Confusion · Thought acceleration · Increased nature relatedness · Multiple thought streams · Analysis enhancement · Creativity enhancement · Memory suppression · Humor enhancement · Cognitive fatigue · Cognitive impairment · Synchronicity · Thought loops · Memory fragmentation · Thought disorganization · Cognitive dysphoria
Pattern recognition enhancement · Cognitive flexibility · Introspection enhancement · Confusion · Thought acceleration · Increased nature relatedness · Multiple thought streams · Analysis enhancement · Creativity enhancement · Memory suppression · Humor enhancement · Cognitive fatigue · Cognitive impairment · Synchronicity · Thought loops · Memory fragmentation · Thought disorganization · Cognitive dysphoria
Simultaneous emotions · Anxiety · Catharsis · Dysphoria
Sociability enhancement · Trust enhancement · Communication enhancement · Flow state · Depersonalization · Boundary dissolution · Ego dissolution · Identity alteration
Depersonalization · Boundary dissolution · Ego dissolution · Identity alteration
Timeline
Gradual awareness of altered state emerges. Initial body sensations — stomach awareness, mild tension, slight restlessness — precede any perceptual changes.
Intensity builds steadily with increasing body load — nausea, trembling, and muscle tension rise. Early color enhancement and visual shifts begin. Bruxism may appear.
Full psychedelic effects — vivid closed-eye geometry with jewel-like imagery, color enhancement, internal hallucinations, altered cognition and thought connectivity. Body load at maximum intensity.
Visual and cognitive effects gradually recede. Body load eases but residual stimulation and wakefulness persist. Appetite may begin to return.
Residual mood shift with mild stimulation and possible physical fatigue. Cognitive baseline slowly returns.
⚠ Do not drive or operate machinery for at least 14 hours after oral ingestion.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- No data
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for 3C-E in any species. No controlled toxicity studies have been performed, and no overdose case reports, emergency department presentations, or fatalities have been attributed to it in the published literature.safety citation needed This absence reflects the compound's rarity, not established safety.
Body load
The most consistently documented adverse effect is significant somatic discomfort. Shulgin described pre-nausea sensations, trembling, and generalized body discomfort at 60 mg oral, concluding that 3C-E is "for most subjects a little too heavy on the body".[4] Bruxism was noted at 40 mg.
Cardiovascular effects
No cardiovascular data specific to 3C-E exist. Serotonergic phenethylamine psychedelics as a class produce elevated heart rate, increased blood pressure, and vasoconstriction.[12] These effects are expected with 3C-E but have not been measured.inferred
Hyperthermia
Overheating is a class-level concern for serotonergic psychedelics, particularly at higher doses and in settings involving physical exertion or high ambient temperature.[12] No temperature data have been recorded for 3C-E.
Psychological Risks
No controlled data on 3C-E's psychological adverse effects exist. Class-level risks for all serotonergic psychedelic serotonin 2A receptor agonists include:
- Acute anxiety, panic, and confusion: Dose-dependent and modulated by set and setting. Higher doses carry greater risk of overwhelming experiences.
- Psychotic episodes: Possible in predisposed individuals. The prolonged duration of 3C-E (8–12 hours) extends the window of vulnerability relative to shorter-acting psychedelics.
- Hallucinogen persisting perception disorder (HPPD): Reported across the serotonergic psychedelic class with generally low prevalence and frequently self-resolving course.[13] No HPPD cases have been attributed to 3C-E.
Shulgin's reports suggest a steep dose-response curve: 40 mg produced manageable effects with a strong sense of control, while 60 mg reached high intensity with significant body and perceptual load.[4]
Tolerance & Dependence
3C-E is not habit-forming. Serotonergic psychedelics have very low abuse liability, are not positively reinforcing in animal self-administration models, and produce rapid tolerance that inherently limits compulsive use.
Tolerance to 5-HT₂A-mediated effects develops within 24 hours of a single dose, with cross-tolerance between different psychedelic 5-HT₂A agonists.[5] This mechanism is 5-HT₂A receptor activation-dependent and independent of β-arrestin-2 signaling.[5]
A caveat applies to the mescaline structural analog class: repeated mescaline administration in rats did not produce serotonin₂ downregulation, unlike repeated LSD.[11] Whether 3C-E follows the mescaline pattern or the indole psychedelic pattern has not been determined.inferred
No physical dependence, withdrawal, or compulsive use patterns have been reported for 3C-E or any 3C-series compound.
Drug Interactions
Serotonergic combinations
Tramadol: Combining 3C-E with tramadol carries risk of serotonin syndrome. Tramadol blocks serotonin reuptake, and adding direct 5-HT₂A agonism creates a pharmacodynamic interaction that may trigger serotonin syndrome.[14] This interaction is classified as dangerous.
MAOIs: Monoamine oxidase inhibitors could extend 3C-E's duration and intensify effects by slowing breakdown of endogenous serotonin during receptor activation. Although 3C-E does not itself release monoamines,[2] this combination warrants extreme caution.safety citation needed
SSRIs and SNRIs: Chronic SSRI use may blunt psychedelic effects through 5-HT₂A receptor downregulation. Acute combination increases total serotonergic burden. Clinical significance for 3C-E is uncharacterized.inferred
Seizure risk
Lithium: lithium combined with serotonergic psychedelics has been associated with seizures in case reports across the class. This combination is considered dangerous.safety citation needed
Metabolic interactions
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine): If CYP2D6 is the primary metabolic enzyme for 3C-E (inferred from related compound data[10]), potent inhibitors could reduce clearance and prolong the already extended duration.inferred
Cannabis
The interaction between cannabis and 3C-E has not been characterized. Cannabis may intensify anxiety and perceptual effects during psychedelic experiences.
Contraindications
No 3C-E-specific contraindication data exist. The following are inferred from the serotonergic psychedelic class inferred:
- Personal or family history of psychotic disorders: 5-HT₂A agonists may trigger or worsen psychotic episodes in predisposed individuals.
- Current lithium therapy: Seizure risk when combined with serotonergic psychedelics.
- Current MAOI therapy: Risk of potentiated serotonergic effects and unpredictable intensity.
- Severe heart conditions: Elevated heart rate and blood pressure expected with phenethylamine psychedelics.[12]
- Pregnancy: No reproductive toxicity data exist; standard precautionary exclusion applies.
- Seizure disorders: Phenethylamine psychedelics may lower seizure threshold at high doses.[12]
Harm Reduction[edit]
Forms & Identification
3C-E circulates almost exclusively as a white crystalline powder (hydrochloride salt), visually indistinguishable from dozens of other research chemicals. Without reagent testing and precise weighing, there is no way to confirm identity or dose from appearance alone. The steep dose-response curve between 40 and 60 mg makes milligram-scale accuracy critical — volumetric estimation or eyeballing introduces unacceptable risk with this compound.
Guidelines
- Weigh every dose on a milligram-capable scale (±2 mg accuracy or better). The difference between a moderate and overwhelming experience is 20 mg.
- Start at the low end of the active range (30 mg) when trying a new batch or using the compound for the first time.
- Allow at least 2 hours before considering the experience sub-threshold — redosing before full onset can push total exposure into uncomfortable territory.
- Eat lightly 2–3 hours before dosing to reduce nausea without slowing absorption excessively.
- Choose a physically comfortable, temperature-controlled environment. Body load is the dominant adverse feature and is worsened by physical stress.
- Have a trusted, sober companion present, especially above 40 mg. The 8–12 hour duration makes this a significant time commitment.
- Keep water accessible throughout. Maintain normal hydration without overdrinking.
Aftercare & Integration
The extended duration and heavy body load of 3C-E often leave users physically drained. Plan for a full rest day following a session. Sleep may be difficult in the final hours; a dark, quiet environment without screens helps.
Journaling within 24–48 hours captures detail that fades quickly. For experiences that were emotionally intense or psychologically challenging, talking with a trusted friend or a therapist experienced with psychedelic integration can help contextualize what emerged. Persistent distress, intrusive imagery, or perceptual changes lasting more than a few days warrant professional consultation.
Recovery & Support
3C-E does not produce physical dependence, and compulsive use patterns are not characteristic of the psychedelic class. If psychedelic use is becoming a pattern of avoidance — a way to escape rather than explore — that pattern itself may benefit from examination.
Resources for support include the Fireside Project (62-FIRESIDE / 623-473-7433), a psychedelic peer support line, and MAPS integration therapist directories. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Severe, uncontrollable vomiting or inability to keep fluids down
- Chest pain, racing heartbeat that feels irregular, or difficulty breathing
- Seizure activity or loss of consciousness
- Self-harm behavior or complete disconnection from reality
- Body temperature noticeably elevated to the touch
Immediate steps:
- 1. Move the person to a cool, quiet space.
- 2. If conscious, reassure them calmly and help them find a comfortable position.
- 3. Do not restrain them unless they are in immediate danger of harming themselves.
- 4. If they are unconscious, place them in the recovery position (on their side, airway clear).
- 5. Call emergency services if any of the red flags above are present.
What to tell the dispatcher:
Name the substance (3C-E, a psychedelic amphetamine), approximate dose, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
3C-E is not widely scheduled as a named substance. Its legal status in most jurisdictions depends on structural analog provisions, blanket psychoactive substance bans, or new psychoactive substance (NPS) frameworks rather than substance-specific scheduling. As a structural and pharmacological analog of mescaline, 3C-E falls within the scope of analog legislation in multiple jurisdictions even where it is not named explicitly.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Potentially prosecutable under the Federal Analogue Act (21 U.S.C. § 813) as a structural and pharmacological analog of mescaline (Schedule I). Prosecution requires proof of intent for human consumption.[6] |
| United Kingdom | Illegal | Prohibited under the Psychoactive Substances Act 2016, which bans production, supply, and possession with intent to supply of any psychoactive substance not specifically exempted.[6] |
| Germany | Controlled (NpSG) | Scheduled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG), effective November 26, 2016. Possession is prohibited but not penalized; production, import, distribution, and administration are criminal offenses.[6] |
| Canada | Unconfirmed for 3C-E | Mescaline is Schedule III under the Controlled Drugs and Substances Act (CDSA). Analog status of 3C-E under Canadian law could not be confirmed in available sources.citation needed |
| Australia | Unconfirmed for 3C-E | Mescaline is Schedule 9 (Prohibited Substance) under the Poisons Standard. 3C-E likely falls under analog provisions but specific scheduling could not be confirmed.citation needed |
Analog act considerations
In the United States, the Federal Analogue Act extends Schedule I and II controls to substances "substantially similar" in chemical structure or pharmacological effect to a scheduled compound, provided they are intended for human consumption. 3C-E meets both the structural criterion (mescaline analog with α-methylation and 4-ethoxy substitution) and the pharmacological criterion (serotonin 2A receptor agonist producing psychedelic effects). Labeling as "not for human consumption" or "research chemical" creates legal ambiguity, though this defense has been challenged in federal prosecutions.
references
- [1]
- [2] ^abcdMatsumoto T, Maeno Y, Kato H, Seko-Nakamura Y, Monma-Ohtaki J, Ishiba A, Nagao M, Aoki Y (2014) 5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: a comparative study using in vivo microdialysis — European Neuropsychopharmacology doi:10.1016/j.euroneuro.2014.04.009
- [3]
- [4]
- [5] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6]